JP2024518776A - 抗adgre2抗体及びその使用 - Google Patents

抗adgre2抗体及びその使用 Download PDF

Info

Publication number
JP2024518776A
JP2024518776A JP2023565453A JP2023565453A JP2024518776A JP 2024518776 A JP2024518776 A JP 2024518776A JP 2023565453 A JP2023565453 A JP 2023565453A JP 2023565453 A JP2023565453 A JP 2023565453A JP 2024518776 A JP2024518776 A JP 2024518776A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565453A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518776A5 (cg-RX-API-DMAC7.html
Inventor
バナージー、アンタラ
ヒー、シンユエ
ジェニングス、ショーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2024518776A publication Critical patent/JP2024518776A/ja
Publication of JP2024518776A5 publication Critical patent/JP2024518776A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023565453A 2021-04-26 2022-04-25 抗adgre2抗体及びその使用 Pending JP2024518776A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163179756P 2021-04-26 2021-04-26
US63/179,756 2021-04-26
PCT/US2022/026161 WO2022232035A1 (en) 2021-04-26 2022-04-25 Anti-adgre2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024518776A true JP2024518776A (ja) 2024-05-02
JP2024518776A5 JP2024518776A5 (cg-RX-API-DMAC7.html) 2025-05-07

Family

ID=81648880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565453A Pending JP2024518776A (ja) 2021-04-26 2022-04-25 抗adgre2抗体及びその使用

Country Status (17)

Country Link
US (1) US12540178B2 (cg-RX-API-DMAC7.html)
EP (1) EP4330283A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024518776A (cg-RX-API-DMAC7.html)
KR (1) KR20240004287A (cg-RX-API-DMAC7.html)
CN (1) CN117580860A (cg-RX-API-DMAC7.html)
AR (1) AR125450A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022266583A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020371A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214355A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003174A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013195A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP23088752A (cg-RX-API-DMAC7.html)
IL (1) IL307940A (cg-RX-API-DMAC7.html)
MX (1) MX2023011712A (cg-RX-API-DMAC7.html)
PE (1) PE20242205A1 (cg-RX-API-DMAC7.html)
TW (1) TW202305003A (cg-RX-API-DMAC7.html)
WO (1) WO2022232035A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022266583A1 (en) 2021-04-26 2023-10-19 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
PE20241789A1 (es) 2021-04-26 2024-09-06 Millennium Pharm Inc Anticuerpos anti-clec12a y usos de los mismos
JP2024514974A (ja) 2021-04-26 2024-04-03 メモリアル スローン-ケタリング キャンサー センター Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用
CN120152735A (zh) * 2022-10-25 2025-06-13 武田药品工业株式会社 Adgre2嵌合受体nk细胞组合物和使用方法
EP4713363A1 (en) * 2023-05-15 2026-03-25 Syzygymed Inc Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250361317A1 (en) * 2024-05-24 2025-11-27 Janssen Biotech, Inc. Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544085A (ja) * 2010-11-05 2013-12-12 トランスバイオ リミテッド 内皮前駆細胞のマーカーおよびその使用
WO2018027197A1 (en) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
JP2019506136A (ja) * 2015-11-19 2019-03-07 アッヴィ・ステムセントルクス・エル・エル・シー 新規抗emr2抗体及び使用方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3681787D1 (de) 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
HK1008049A1 (en) 1987-09-11 1999-04-30 Whitehead Institute For Biomedical Research Transduced fibroblasts and use therefor
ATE110108T1 (de) 1987-12-11 1994-09-15 Whitehead Biomedical Inst Genetische modifizierung von endothelialen zellen.
DE68927996T2 (de) 1988-02-05 1997-12-04 Hughes Howard Med Inst Modifizierte hepatozyten und deren anwendung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69123981T3 (de) 1990-10-31 2006-06-14 Cell Genesys Inc Nützliche retrovirale vektoren für die gentherapie
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
JP4383168B2 (ja) 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US20040102469A1 (en) 2002-09-13 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for reducing the mortality rate
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
CA2693771A1 (en) 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
EP2622074B1 (en) 2010-09-30 2014-11-12 Board Of Trustees Of Northern Illinois University Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
SG11202010763VA (en) 2018-05-03 2020-11-27 Univ Texas Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
AU2022266583A1 (en) 2021-04-26 2023-10-19 Millennium Pharmaceuticals, Inc. Anti-adgre2 antibodies and uses thereof
PE20241789A1 (es) 2021-04-26 2024-09-06 Millennium Pharm Inc Anticuerpos anti-clec12a y usos de los mismos
JP2024514974A (ja) 2021-04-26 2024-04-03 メモリアル スローン-ケタリング キャンサー センター Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用
CN114106199B (zh) 2021-11-19 2022-07-12 广州百暨基因科技有限公司 靶向adgre2的嵌合抗原受体及其应用
CN120152735A (zh) 2022-10-25 2025-06-13 武田药品工业株式会社 Adgre2嵌合受体nk细胞组合物和使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544085A (ja) * 2010-11-05 2013-12-12 トランスバイオ リミテッド 内皮前駆細胞のマーカーおよびその使用
JP2019506136A (ja) * 2015-11-19 2019-03-07 アッヴィ・ステムセントルクス・エル・エル・シー 新規抗emr2抗体及び使用方法
WO2018027197A1 (en) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof

Also Published As

Publication number Publication date
TW202305003A (zh) 2023-02-01
BR112023020371A2 (pt) 2024-02-06
WO2022232035A1 (en) 2022-11-03
ECSP23088752A (es) 2024-01-31
US12540178B2 (en) 2026-02-03
US20230018888A1 (en) 2023-01-19
AR125450A1 (es) 2023-07-19
AU2022266583A1 (en) 2023-10-19
MX2023011712A (es) 2023-10-12
CO2023013195A2 (es) 2023-10-19
AU2022266583A9 (en) 2023-10-26
EP4330283A1 (en) 2024-03-06
KR20240004287A (ko) 2024-01-11
PE20242205A1 (es) 2024-11-19
CL2023003174A1 (es) 2024-05-24
CA3214355A1 (en) 2022-11-03
CN117580860A (zh) 2024-02-20
IL307940A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
US12540178B2 (en) Anti-ADGRE2 antibodies and uses thereof
JP6850255B2 (ja) 抗−cd47抗体及びその使用
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
US12600784B2 (en) Anti-Clec12A antibodies and uses thereof
WO2022081799A1 (en) Compositions and methods for treatment of thyroid eye disease
CN122003247A (zh) 治疗活动性和慢性甲状腺眼病的方法
JP7829595B2 (ja) 補体因子dを標的とする抗体及びその使用
IL324043A (en) Trop2 binders and conjugates thereof
US20250122286A1 (en) Antibody optimization
JP7769635B2 (ja) 抗cd19抗体及びその使用
EA051556B1 (ru) Антитела к adgre2 и их применение
EA050975B1 (ru) Антитела к cd19 и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260521

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260804